Toggle Navigation


In collaboration with national and international colleagues, Gynuity conducted a study in 26 villages in rural Gambia comparing misoprostol to ergometrine for prevention of postpartum hemorrhage. The misoprostol group experienced lower incidence of measured blood loss ≥500 mL and postpartum hemoglobin <8 g/dL, although the differences were not statistically significant. The results demonstrate that 600 mcg of oral misoprostol is a promising drug to prevent life-threatening postpartum hemorrhage in this setting. The results were published by Walraven et al. in British Journal of Obstetrics and Gynaecology (Sep 2005), 112(9), pp. 1277-1283. 

Back to World Map